← Back to Clinical Trials
Recruiting NCT07294989

NCT07294989 The Effective Blood Concentration of Ciprofol

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07294989
Status Recruiting
Phase
Sponsor Peking University Shenzhen Hospital
Condition Thyroid Disease
Study Type OBSERVATIONAL
Enrollment 101 participants
Start Date 2025-07-01
Primary Completion 2026-06-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 65 Years
Study Type OBSERVATIONAL
Interventions
Ciprofol

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 101 participants in total. It began in 2025-07-01 with a primary completion date of 2026-06-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

1. Eligible patients were selected and enrolled in the study. 2. General anesthesia was induced using ciprofol in all participants, with standardized evaluation of consciousness levels during induction. 3. The patients' pain and cognition are followed up after surgery.

Eligibility Criteria

Inclusion Criteria: * Patients aged 18-65 years * Scheduled for elective thyroidectomy * ASA physical status classification I-II * Willing to participate and providing written informed consent Exclusion Criteria: * Recent use of sedatives or opioid analgesics * Severe hepatic or renal dysfunction defined as:Child-Pugh class C (score ≥10), Creatinine clearance \<35 mL/min ,Requiring preoperative dialysis * Significant cardiovascular comorbidities * Body mass index ≥35 kg/m² or \<18.5 kg/m² * Known hypersensitivity or adverse reactions to propofol/ciprofol * Neuropsychiatric disorders including:Alzheimer's disease,History of cerebrovascular events,Traumatic brain injury,Space-occupying brain lesions,Other significant neurological deficits

Contact & Investigator

Central Contact

Tao Luo

✉ 496855048@qq.com

📞 +86 135 1082 0779

Frequently Asked Questions

Who can join the NCT07294989 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 65 Years, studying Thyroid Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07294989 currently recruiting?

Yes, NCT07294989 is actively recruiting participants. Contact the research team at 496855048@qq.com for enrollment information.

Where is the NCT07294989 trial being conducted?

This trial is being conducted at Shenzhen, China.

Who is sponsoring the NCT07294989 clinical trial?

NCT07294989 is sponsored by Peking University Shenzhen Hospital. The trial plans to enroll 101 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology